AVITA Medical : JP Morgan Healthcare Conference Presentation

useonlyJanuary		2022
ersonal	ASX: AVH
NASDAQ: RCEL

©Copyright 2021 AVITA Medical. All Rights Reserved.

Legal Disclaimers

Certain statements in this presentation and the accompanying oral commentary are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, onlytechnology platform, development strategy, prospective products, pipeline and milestones, regulatory objectives, expected payments from and outcomes of collaborations, and likelihood of success, are forward-looking statements. Such statements are predictions only and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or

implied by the forward-looking statements. These risks and uncertainties include, among others, the costs, timing and results of clinical trials and other development activities; the uncertainties inherent in the initiation and enrollment of clinical trials; the uncertainties associated with the COVID-19 pandemic; the unpredictability of the timing and results of regulatory submissions and reviews; market acceptance for approved products and innovative therapeutic treatments; competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting risks and litigation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are

useb yond our control, you should not rely on these forward-looking statements as predictions of future events. More information concerning AVITA Medical as well as the aforementioned risks and uncertainties is available in our public filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and our most recent Annual Report on Form 10-Kfor the year ended June 30, 2021. We are providing this information as of its date and do not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise, except as required by law. Additional information may be available in press releases or other public announcements and public filings made after the date of this presentation.

AVITA Medical's products are Rx only. Please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse

events.

In the United States, RECELL® is approved for use in patients suffering acute thermal burns. Use of RECELL in other patient populations is either prohibited by United States law or may be made available pursuant to a relevant investigational device exemption granted by the FDA (and likewise limited by United States law to investigational use

o ly).

ersonal

2

Value Creation

	Recent Key Accomplishments
	•	Vitiligo Pivotal Trial: Enrollment Completed
only•	Soft Tissue Pivotal Trial: Enrollment Completed
	•	Transitional Pass-Through Payment Application
use	Approved by CMS for Reimbursement in Outpatients
	• EB: Initial Proof of Concept for Delivery of Genetically
		Modified Skin Cells in Suspension
	• Telomerase/Rejuvenation: Initial Proof of Concept on
ersonal	Delivery of Reverse-Aged Skin Cells
Quarter Ending December '21, Total Revenue Growth of
	•
		+35% vs Same Quarter Prior Year
	•	FDA Approval of Pediatric Label Expansion
	•	New Ease of Use RECELL Device under FDA Review

Quart rs referenced in calendar year. As of January 1, 2022 Avita Medical will report on a calendar year basis.

Projected Key Milestones

• Vitiligo FDA Submission / Vitiligo Commercial

	launch	H2	22 /
• Soft Tissue FDA Submission / Soft Tissue	H2	23
	Commercial Launch
•	Outpatient Launch
•	PMDA Approval of Burns in Japan	H1 22
• FDA Approval of New 'Ease of Use' RECELL
	Device
• IND Enabling Studies (EB & Rejuvenation)	H2 22

3

AVITA Leadership Team

only			Erin Liberto
Dr. Michael S. Perry	Michael Holder	Andrew Quick	Kathy McGee	Donna Shiroma
use	CEO	CFO	CCO	CTO	COO	General Counsel
	>30 years experience	>20 years experience	>25 years experience	>25 years experience	>20 years experience
>30 years experience
	Affiliations:	Affiliations:	Affiliations:	Affiliations:	Affiliations:	Affiliations:
ersonal						4

One Platform. Endless Possibilities.

only	RECELL delivers healthy skin cells	RECELL enables
	regeneration of
		healthy skin
	Autologous skin cells
use	are sprayed on patient
Healthy skin processed
	using the RECELL System
ersonal	Patch of healthy skin
removed from patient
		Technology platform
		benefits a wide array of
Free cells modulate and catalyze the healing process	skin defects and wounds
irrespective of etiology

In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

Vitiligo

Trauma

Burns / Scalds

Chronic Wounds

Scar Revision

Infectious Disease Cancer Reconstruction

Genodermatoses Regenerative Dermatology

5